Subsequently, SREBP-1c enters the nucleus and activates adipogenesis genes, participating in the regulation of downstream fatty acid synthesis rate-binding enzyme ACC and fatty acid oxidation rate-binding enzyme CPT1, resulting in liver lipid metabolism disorder (Osna et al., 2017; Ge et al., 2020). The gene discussed is SREBF1; the disease is medical procedure.